But he implied that only misguided contrarians could dispute that lecanemab established the amyloid hypothesis as fact, and that such drugs would illuminate the path to solve the Alzheimer’s puzzle.

With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially be dosed as ...